

Sponsored Symposium, Seminar

LS1 Luncheon Seminar 1

12:20 - 13:10

October 31 (Day 1) Room 1

Update ES-SCLC 1st line treatment

Moderator: Miyako Satouchi (Department of Thoracic Oncology, Hyogo Cancer Center)

Speaker: Daniel S W Tan (Division of Medical Oncology / Division of Clinical Trials & Epidemiological Sciences, National Cancer Centre Singapore)

Sponsored by AstraZeneca K.K.

LS2 Luncheon Seminar 2

12:20 - 13:10

October 31 (Day 1) Room 2

Perioperative therapy for Non-Small cell lung cancer

Moderator: Kazuhisa Takahashi (Department of Respiratory Medicine Juntendo University Graduate School of Medicine)

Review of treatment using ICI in the perioperative period

Speaker 1: Heather Wakelee (Department of Medicine, Division of Oncology Stanford University Stanford Cancer Institute)

irAE management and shared decision making of IO therapy in the perioperative setting

-How to use IMpower010-

Speaker 2: Yuko Oya (Fujita Health University, Department of Respiratory Medicine & Clinical Allergy)

Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.

LS3 Luncheon Seminar 3

12:20 - 13:10

October 31 (Day 1) Room 3

Improving cure rates in early-stage NSCLC, current data and future perspectives

Moderator: Tetsuya Mitsudomi (Izumi City General Hospital / Faculty of Medicine, Kindai University)

Speaker: Jamie E. Chaft (Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center)

Sponsored by MSD K.K.

LS11 Luncheon Seminar 11

11:50 - 12:40

November 1 (Day 2) Room 2

20 Years of Journey and the Arrival of a Game-Changing Therapy

Moderator: Yuichiro Ohe (Department of Thoracic Oncology, National Cancer Center Hospital)

The Long and Winding Road to Targeting EGFR Ex20ins

Speaker 1: Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)

EGFR exon 20 ins mutated NSCLC: new standards

Speaker 2: Nicolas Girard (Department of Medical Oncology, Institute Curie, Paris)

Sponsored by Janssen Pharmaceutical K.K.

LS16 Luncheon Seminar 16

11:50 - 12:40

November 1 (Day 2) Room 7

Strategies for First-line treatment of ALK-positive non-small cell lung cancer

Moderator: Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)

Speaker: Myung-Ju Ahn (Division of Hemato-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)

Sponsored by Takeda Pharmaceutical Company Limited

LS17 Luncheon Seminar 17

11:50 - 12:40

November 1 (Day 2) Room 8

**Treatment strategy when we MET NSCLC patients with METex14 skipping mutation
-with my clinical experience-**

Moderator: Takashi Seto (Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center)

Speaker: Stephen V. Liu (Thoracic Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC)

Sponsored by Novartis Pharma K.K.

LS20 Luncheon Seminar 20

12:00 - 12:50

November 2 (Day 3) Room 1

Updated Perioperative Treatment Strategy for Early-Stage NSCLC

Moderator: Tetsuya Mitsudomi (Izumi City General Hospital / Kindai University)

Speaker: Roy S. Herbst (Smilow Cancer Hospital / Yale Cancer Center / Yale School of Medicine)

Sponsored by AstraZeneca K.K.

LS21 Luncheon Seminar 21

12:00 - 12:50

November 2 (Day 3) Room 2

Treatment sequence in EGFR mutated NSCLC

Moderator: Kazuhiko Nakagawa (Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan)

Kazuto Nishio (Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan)

Up to date : EGFRm NSCLC Treatment

Speaker 1: Miyako Satouchi (Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan)

EGFRm NSCLC Treatment from a US Physician's Perspective

Speaker 2: Joseph A. Treat (Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA)

Sponsored by Eli Lilly Japan

ES1 Evening Seminar 1

18:30 - 19:20

October 31 (Day 1) Room 1

Current treatment strategy for EGFR Ex20 ins mutated NSCLS

Moderator: Makoto Nishio (Thoracic Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)

New clinical strategies for EGFR Ex20 ins mutated NSCLC

Speaker 1: Nicolas Girard (Chair of the Department of Medical Oncology, Institute Curie, Paris)

Discussion: Case Report

How are skin toxicities of Amivantamab-Chemotherapy managed or treated?

Speaker 2: Akira Ono (Division of Thoracic Oncology, Shizuoka Cancer Center)

Sponsored by Janssen Pharmaceutical K.K., Medical Affairs Division

ES2 Evening Seminar 2

18:30 - 19:20

October 31 (Day 1) Room 2

Paradigm Shift in ALK+ NSCLC ~ Lorlatinib: 5-year long follow up from the CROWN study ~

Moderator: Yasushi Goto (National Cancer Center Hospital)

Speaker: Ross Soo (National University Cancer Institute, Singapore)

Sponsored by Pfizer Japan Inc.

ES6 Evening Seminar 6

18:30 - 19:20

October 31 (Day 1) Room 8

ADVANCES IN THE TREATMENT OF HER2 MUTATION-POSITIVENSCLC

Moderator: Tatsuya Yoshida (Department of Thoracic Oncology/Experimental Therapeutics National Cancer Center Hospital)

Speaker: Luis Paz Ares (Head of Oncology Department Hospital 12 de Octubre, Madrid)

Sponsored by Daiichi Sankyo Co.,Ltd

ES8 Evening Seminar 8

18:10 - 19:00

November 1 (Day 2) Room 2

Unraveling the complexities of Small Cell Lung Cancer: Innovations, Challenges, and Future Directions in Treatment

Moderator: Kazuhisa Takahashi (Department of Respiratory Medicine, Juntendo University)

Speaker: David P. Carbone (Internal medicine, The Ohio State University)

Sponsored by Amgen K.K. Medical Affairs